Business
Exercise of Options and Total Voting Rights
Exercise of Options and Total Voting Rights.
About this update from Provexis Plc
[{"type":"text","content":"\n \n \n 17 May 2022\n \n \n \n \n \n \n \n \n Provexis plc\n \n \n \n \n \n \n \n \n \n (\"Provexis\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Exercise of Options and Total Voting Rights\n \n \n \n \n \n \n Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that application has been made for the admission to AIM of 7,000,000 ordinary shares of 0.1p each in the Company ('New Provexis Shares'), pursuant to the exercise of options by a consultant to the Company.\n \n \n \n \n \n The New Provexis Shares will when issued rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis. Application has been made to the London Stock Exchange for the 7,000,000 New Provexis Shares to be admitted to trading on AIM. It is expected that admission will become effective and that trading in the New Provexis Shares will commence on or around 23 May 2022 ('Admission').\n \n \n \n \n \n Following Admission, the Company's enlarged issued share capital will comprise 2,217,821,523 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 2,217,821,523 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n Provexis plc\n \n \n Dawson Buck, Chairman\n \n \n Ian Ford, CEO\n \n \n \n \n \n \n \n Tel: 07490 391888\n \n \n [email protected]\n \n \n \n \n \n \n Allenby Capital Limited\n \n \n Nick Naylor / Liz Kirchner\n \n \n \n \n Tel: 020 3328 5656\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes for editors\n \n \n \n \n \n \n \n About Provexis plc\n \n \n \n AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.\n \n \n \n \n \n Fruitflow is a natural, breakthrough ingredient that helps with platelet aggr...